



**Isfahan University of Medical Sciences  
Faculty of medicine  
Immunology Department**

**Thesis Project For  
M.Sc. Degree**

**Evaluation of CD11b and CD64 markers in Neonatal Sepsis for  
rapid diagnosis and compare with blood culture  
and serum CRP level.**

*By:*

**Vajiheh ostadi**

*Supervisors:*

**Adib M. (professor)**

**Navaei F. (Associate professor)**

**Saheb fosoul F.(MSC)**

*Consultants:*

**Oreizi F. (MSc)**

**Summary:**

**Introduction:** Neonatal sepsis is a life-threatening disease with an incidence of 1 to 10 per 1000 live births and a mortality rate of 15% to 50%. The clinical signs are nonspecific and indistinguishable from those caused by a variety of neonatal noninfective disorders. The aim of this study was to determine sensitivity, specificity, positive and negative predictive value of CD11b and CD64, two neutrophil markers, in early diagnosis of neonatal sepsis.

**Methods:** In this study were comprised 65 neonates with a gestational age of 27 to 38 weeks who suspected for sepsis within 28 days of life. 1 cc of whole blood was obtained from neonates to determine of CD11b and CD64 expression on peripheral blood neutrophils by flow cytometry. CRP was measurement qualitatively. Neonates were classified into two groups. Classification was based on positive blood culture. In the sepsis group (n = 8), all of neonates were positive blood culture and had clinical symptoms. In the suspected group (n = 57), each neonate had at least 1 clinical sign but negative blood culture. 12 healthy term neonates with physiologic hyperbilirubinemia classified in control group.

**Results:** Neutrophil CD11b was elevated in sepsis and suspected group but this increase was not significant between three groups (P = 0.69). CD64 was elevated in sepsis group and this increase was significant (P<0.001). CRP in 4 neonates with sepsis was positive and other neonates were negative.

Sensitivity and specificity of CD11b and CD64 were 75%, 100%, 100% and 92.3% respectively. The negative and positive predictive value of CD11b and CD64 for identifying sepsis were 86%, 100%, 100% and 88% respectively.

**Discussion:** Sensitivity of CD64 was higher than CD11b in neonatal sepsis. Although, specificity of CD11b was higher than CD64. Combining the use of CD64 with CD11b further enhances the ability to diagnosis infection and improve the sensitivity and negative predictive value to 100%.

**Key word:** Neonatal sepsis, CRP, CD11b, CD64.

# Contents

---

---

**Chapters****pages**

---

---

## Chapter I.

1.1. Introduction .....	1
1.2. Definition of Bacteremia, Sepsis and septicemia .....	1
1.3. Development of the immune system .....	2
1.4. Physiology of immune system in neonates .....	4
1.5. Neonatal sepsis .....	5
1.5.1. Epidemiology .....	5
1.5.2. Risk factors .....	6
1.5.2.1. Neonatal factors .....	6
1.5.2.2. Maternal factors .....	7
1.5.2.3. Environmental factors .....	7
1.5.3. Clinical manifestations .....	8
1.5.4. Diagnosis .....	10
1.5.4.1. Blood culture .....	10
1.5.4.2. White Blood Cell (WBC) count and differential .....	11
1.5.4.3. C- reactive protein (CRP) .....	12
1.5.4.3.1. Regulation and expression .....	13
1.5.4.3.2. Structure .....	14
1.5.4.3.3. Function .....	14
1.5.4.4. CD11b .....	18
1.5.4.4.1. Structure .....	18
1.5.4.4.2. Function .....	20
1.5.4.5. FcγRI (CD64) .....	22
1.5.4.5.1. CD64 (FcγRI) structure .....	22
1.5.4.5.2. FcγR function .....	25
1.6. Flow cytometry .....	27
1.6.1. Light scatter .....	28
1.6.2. Fluorescence .....	29
1.6.3. Display and interpretation of flow cytometry data .....	30
1.6.4. Applications of flow cytometry .....	32
1.6.4.1. DNA content .....	32

# Contents

<b>Chapters</b>	<b>pages</b>
1.6.4.2. Evaluation of cell-surface markers.....	33
1.6.4.3. Cell sorting .....	34
1.6.5. Why use flow cytometry.....	35
<b>Chapter II.</b>	
2.1. Major aim .....	36
2.2. Minor aims .....	36
2.3. Applied aim .....	37
2.4. Hypothesis and questions .....	37
<b>Chapter III.</b>	
3.1. Equipments .....	38
3.2. Buffers and solutions.....	38
3.3. Reagents .....	39
3.4. Blood culture .....	39
3.5. Patients .....	40
3.6. Measurement of CD11b.....	40
3.7. Measurement of CD64.....	41
3.8. Measurement of CRP.....	43
3.9. Blood culture method .....	43
3.10. Manner of study.....	43
3.11. Statistic analysis .....	43
<b>Chapter IV.</b>	
4.1. Result .....	45
<b>Chapter V.</b>	
5.1. Discussion .....	56
<b>Suggestions</b> .....	62
<b>References</b> .....	63
<b>Abbreviations</b> .....	71

## List of Tables

<b>Tables</b>	<b>pages</b>
Table 1.1. Factors increasing the risk of sepsis in a neonate.....	8
Table 1.2. Signs of sepsis in the neonate.....	9
Table 1.3. Protein and non- protein CR3 ligands .....	21
Table 1.4. General characteristics of human leukocyte IgG receptors.....	25
Table 1.5. Common fluorescent dyes .....	30
Table 4.1. Classification of study groups and their numbers .....	45
Table 4.2. Distribution of sex in the study groups.....	46
Table 4.3. Type of delivery in the study groups .....	46
Table 4.4. The mean of gestational age and birth weight in different groups .....	47
Table 4.5. The mean of Apgar score at 1 and 5 minute after birth in different groups .....	47
Table 4.6. Result of blood culture in sepsis group .....	47
Table 4.7. Number of neonates with positive CRP in three groups .....	48
Table 4.8. The mean of CD11b and CD64 expression in different groups .....	49
Table 4.9. Sensitivity, specificity, positive and negative predictive value of CD11b and CD64 in diagnosis of sepsis .....	55

## List of Figures

<b>Figures</b>	<b>pages</b>
Figure 1.1. Structure of CRP protomer .....	14
Figure 1.2. Schematic map of the human CR3 $\alpha$ chain.....	19
Figure 1.3. CR3 signaling pathway .....	21
Figure 1.4. Fc $\gamma$ R .....	24
Figure 1.5. structural heterogeneity of leukocyte Fc $\gamma$ R.....	24
Figure 1.6. A rendition of flow cytometer .....	27
Figure 1.7. A schematic of fluorescence detection by a flow cytometer and a schematic of cell sorting by a flow cytometer .....	28
Figure 1.8. A dotplot of flow cytometry data.....	31
Figure 1.9. A histogram of flow cytometry data .....	32
Figure 1.10. CD4 and CD8 T cells analysed by flow cytometry .....	34
Figure 3.1. Flow cytometric analysis of CD64 expression on neutrophils.....	42
Figure 3.2. Flow cytometric analysis of CD11b expression on neutrophils.....	42
Figure 4.1. Percentage of CD11b expression in different groups .....	49
Figure 4.2. Percentage of CD64 expression in different groups .....	50
Figure 4.3. Comparison of CD11b expression in early sepsis group and control group.....	51
Figure 4.4. Comparison of CD11b expression in late sepsis group and control group.....	51
Figure 4.5. Comparison of CD64 expression in early sepsis group and control group.....	52
Figure 4.6. Comparison of CD64 expression in late sepsis group and control group.....	52
Figure 4.7. Correlation between neutrophil CD11b and CD64 expression levels .....	53
Figure 4.8. CD11b expression differences between control group with suspected and sepsis group.....	54

1. **Young LS.** Sepsis Syndrom. In: **Mandell GL. Bennett JE. Dolin R.** Principles and Practice of Infectious Diseases. 5<sup>th</sup> ed. Philadelphia: *Churchill livingstone*: 2000: 806-819.
2. **McKenney WM.** Neonatal Nursing: Understanding the Neonatal Immune System: High Risk for Infection. *Critical Care Nurse*. 2001; Vol 21, No. 6: 35-47.
3. **Buckley R.** Infections of the neonatal infant. In: **Behrman Re. Kliegman R. Jensen HB.** eds. Behrman: Nelson textbook of Pediatrics. 16<sup>th</sup> ed. Philadelphia, Pa: *WB Saunders CO*; 2000: 538-543.
4. **Lewis D.** Host defense mechanisms against bacteria, fungi, viruses and nonviral pathogens. In: **Polin RA. Fox WD. Fletcher J.** eds. Fetal and Neonatal Physiology. Vol 2.2<sup>nd</sup> ed. Philadelphia, Pa: *WB Saunders Co*; 1998: 1869-1919.
5. **Cole F.** Immunology. In: **Taeusch HW. Ballard RA. Avery Me.** eds. Schaeffer and Avery's Diseases of the newborn. 6<sup>th</sup> ed. Philadelphia, USA, Pa: *WB Saunders CO*: 1991:305-320.
6. **Lawton A.** B-cell development. In: Polin RA, Fox WB, **Fletcher J.** eds. Fetal and neonatal Physiology. Vol 2.2<sup>nd</sup> ed. Philadelphia, Pa; *WB Saunders Co*: 1998: 1924-1930.
7. **Pappas BE.** Primary immunodeficiency disorders in infancy. *Neonatal Netw*.1999;18:13-22.



8. **Lewis D. Wilson C.** Developmental immunology and role of host defenses in neonatal susceptibility to infection. In: **Remington JS. Klein JO**, eds. *Infectious Diseases of the Newborn Infant*. 4<sup>th</sup> ed. Philadelphia, Pa: *WB Saunders Co*: 1995:20-98.
9. **Witek-Janusek L. Cusack C.** Neonatal Sepsis: confronting the challenge. *Crit Care Nurs Clin North Am.* 1994; 6:405-419.
10. **Crockett M.** Physiology of the neonatal immune system. *J Obstet Gynecol Neonatal Nurse.* 1995; 24: 627-634.
11. **Speer C. Johnston RJr.** Neutrophil function in newborn infants. In: **polin RA, Fox WB, Fletcher J**, eds. *Fetal and Neonatal Physiology*. Vol 2.2<sup>nd</sup> ed. Philadelphia, Pa: *WB Saunders Co*: 1998: 1954-1960.
12. **Cole FS.** Bacterial Infections of the Newborn. In: **Taeusch HW. Ballard RA.** *Avery's diseases of the newborn*. 7<sup>th</sup> ed. Philadelphia: *WB Sunders Co.* 1998: 490-512.
13. **Avroy A. Fanaroff RY.** Neonatal- Perinatal Medicine: Diseases of the Fetus and Infant. 7<sup>th</sup> ed. Lowis: *Mosby*; 2002: 860- 392.
14. **Espinosa EL. Montes AT. Luis F. Gonzalez P. Baranda L.** Expression of CD64 as a potential marker of neonatal sepsis. *Pediatric Allergy and Immunology.* 2002:13:319-327.
15. **Panero A. Pacifico L. Rossi N. Mancuso G. Stegagno M. Chiesa C.** Interleukin-6 in neonates with early and late onset infection. *Pediatr Infect Dis J.* 1997:14: 370-5.

16. **Horns KM.** Neoteric Physiologic and Immunologic Methods for Assessing Early-Onset Neonatal Sepsis. *J Perinat Neonat Nurs.* 2000;13(4):50-66.
17. **Speer CH. Bruns A. Gahr M.** Sequential determination of CRP,  $\alpha_1$ -antitrypsin and haptoglobin in neonatal septicaemia. *Acta Paediatr Scand.* 1983;72: 679-83.
18. **Howard MR. Smith RA.** Early diagnosis of septicaemia in preterm infants from examination of peripheral blood films. *Clin Lab Haematolo.* 1999; 21: 365-8.
19. **Da silva O. Ohlsson A. Kenyon C.** Accuracy of leukocyte indices and C-reactive protein for diagnosis of neonatal sepsis: *a critical review.* *Pediatr Infect Dis J.* 1995; 14: 362-6.
20. **Ng PC. Cheng SH. Chui KM.** Diagnosis of late onset neonatal sepsis with cytokines, adhesion molecules, and C-reactive protein in preterm very low birthweight infants. *Arch Dis Child Fetal Neonatal Ed.* 1997; 77: F221-7.
21. **Berger C. Uehligner J. Ghelfi D.** Comparison of C-reactive protein and blood cell count with differential in neonates at risk of septicaemia. *Eur J Pediatr.* 1995; 154: 138-44.
22. **Jurges ES. Henderson DC.** Inflammatory and immunological markers in preterm infants: correlation with disease. *Clin Exp Immunol.* 1996; 105: 551-5.

23. **Volanakis JE.** Human C-Reactive Protein: expression, structure and function. *Review. Molecular Immunology.* 2001; 38: 189-197.
24. **Clyne B. Olshaker JS.** The C-Reactive Protein. *The Journal of Emergency Medicine.* 1999; 17(6): 1019- 1025.
25. **Mold C. Kingzette M. Gewurz H.** C-reactive protein inhibits activation of the alternative pathway by increasing the interaction between factor H and C3b. *J Immunol.* 1984; 133: 882-885.
26. **Mold C. Gewurz H. Du Clos TW.** Regulation of complement activation by C-reactive protein. *Immunopharmacology.* 2001; 42: 23-30.
27. **Stein MP. Mold C. Du Clos TW.** C-reactive protein binding to murine leukocytes requires Fc gamma receptors. *J. Immunol.* 2000; 164: 1514-1520.
28. **Mold C. Gresham HD. Du Clos TW.** Serum amyloid P component and C-reactive protein mediate phagocytosis through murine FcγRs. *J. Immunol.* 2001; 166: 1200-1205.
29. **Edwards KM. Gewurz H. Lint TF. Mold C.** A role for C-reactive protein in the complement-mediated stimulation of human neutrophils by type 27 streptococcus pneumoniae. *J. Immunol.* 1982; 128: 2493-2496.
30. **Rohde LE. Hennekens CH. Ridder PM.** Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. *Am. J. Cardiol.* 1999; 84: 1018-1022.

31. **Ridker PM. Hennekens CH. Buring JE. Rifai N.** C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. *N. Engl. J. Med.* 2000; 342: 836-843.
32. **Simms HH. D' Amico R.** Lipopolysaccharide induces intracytoplasmic migration of the polymorphonuclear leukocyte CD11b/CD18 receptor. *Shock.* 1995; 3: 196-203.
33. **Ng PC. Li K. Wong RPO.** Neutrophil CD64 expression: a sensitive diagnostic marker for late-onset nosocomial infection in very low birthweight infants. *Pediatr Res.* 2002;51: 296-303.
34. **Balsam LB. Liang TW. Parkos CA.** Functional Mapping of CD11b/CD18 Epitopes Important in Neutrophil-Epithelial Interactions: A Central Role of the I Domain. *The Journal of Immunology.* 1998; 160: 5058-5065.
35. **Oxvig C. Springer TA.** Experimental support for a beta-propeller domain in integrin alpha-subunits and a calcium binding site on its lower surface. *Proc Natl Acad Sci USA.* 1998; 95: 4870-5.
36. **Hynes RO.** Integrins: bi-directional, allosteric signaling machines. *Cell.* 2002; 110: 673-87.
37. **Hevia JA. Arenas AG. Barrera D. Velazquez MV.** Gram-negative bacteria and phagocytic cell interaction mediated by complement receptor 3. *FEMS Immunology and Medical Microbiology.* 2002;34: 255-266.

38. **Velazquez MAV. Barrera D. Arenas AG. Rosales C. Hevia JA.** Macrophage- Mycobacterium tuberculosis interactions: role of complement receptor 3. *Microbial Pathogenesis*. 2003; 35: 125-131.
39. **Pol WI. Winkel JGJ.** IgG receptor polymorphisms: risk factor for disease. *Immunogenetics. Review*. 1998; 48: 222-232.
40. **Heijnen IAFM. Vuget MJ. Fanger NA. Graziano RF.** Antigen targeting to myeloid-specific FcγRI/CD64 triggers enhanced antibody responses in transgenic mice. *J Clin Invest*. 1996; 97: 331-338.
41. **Liu C. Goldstein J. Graziano RF. He J.** FcγRI-targeted fusion proteins result in efficient presentation by human monocytes of antigenic and antagonist T cell epitopes. *J Clin Invest*. 1996; 98: 2001-2007.
42. WWW. bioteach. ubc. ca/Molecular Biology/FlowCytometry/
43. **Weave JL.** Introduction to Flow Cytometry. *Methods*. 2000; 21(3): 199-201.
44. **Weirich E. Rabin RL. Maldonado Y. Benitz W.** Neutrophil CD11b expression as a diagnostic marker for early-onset neonatal infection. *J Pediatr*. 1998; 132: 445-51.
45. **Nupponen I. Andersson S. and et al.** Neutrophil CD11b expression and circulating Interleukin-8 as diagnostic markers for early-onset neonatal sepsis. *Pediatrics*. 2001; 108(1): 1-6.

46. **Cui YB. Du LZ. Chen YZ. Yu YB. Wang FM.** Expression of neutrophil adhesion molecule CD11b as an early diagnosis for neonatal sepsis. Abstract. *Zhonghua Er Ke Za Zhi.* 2003; 41(5): 348-51.
47. **Weinschenk NP. Farina A. Bianchi DW.** Premature infants respond to early-onset and late onset sepsis with leukocyte activation. *J Pediatr* 2000; 137: 345-50.
48. **Fjaertoft G. Hakansson L. Edward U. Foucard T. Venge P.** Neutrophils from term and preterm newborn infants express the high affinity Fcγ-receptor I (CD64) during bacterial infection. *Pediatr Res.* 1999; 45: 871-876.
49. **Lehr HA. Krombach F. Munzing S. bodlaj R. Glaubitt Si. Seiffge D. hubner C. et al.** in vitro effects of oxidized low density lipoprotein on CD11b/CD18 and L-selectin presentation on neutrophils and monocytes with relevance for the in vivo. Situation. *Am J Pathol.* 1995; 146: 218-227.
50. **Simms HH. D'Amico R.** Lipopolysaccharide induces intracytoplasmic migration of the polymorphonuclear leukocyte CD11b/CD18 receptor. *Shok.* 1995; 3: 196-203.
51. **de Hass M. Vosseveld PJM. Von dem Borne AEGK. Roos D.** Fcγ receptors of phagocytes. *J Lab Clin Med.* 1995; 126: 330-341.
52. **Sanchez-Mejorada G. Rosales C.** signal transduction by immunoglobulin Fc receptors. *J leukoc Biol.* 1998; 63: 521-533.

53. **Ng PC. Li G. Chui KM. Chu WCW. Li K. Wong RPO. Chik KW. Wong E. Fok TF.** Neutrophil CD64 is a sensitive diagnostic markers for Early-onset neonatal infection. *Pediatr Res.* 2004; 56(5): 796-803.
54. **Ng PC.** Diagnostic markers of infection in neonates. *Review. Arch Dis Child Fetal Neonatal Edu.* 2004; 89: 229- 235.